Top 10 Early Stage Investors: Cancer Therapeutics & Diagnostics
| Rank | Investor Name |
|---|---|
| 1 | Even One Ventures |
| 2 | dRx Capital |
| 3 | Camden Partners |
| 4 | Astellas Venture Management |
| 5 | Cormorant Asset Management |
| 6 | F-Prime Capital |
| 7 | Eli Lilly and Company |
| 8 | Frazier Healthcare Partners |
| 9 | New Enterprise Associates |
| 10 | RA Capital Management |
Early stage activity in this category is led by institutional venture franchises and category specialists. Oncology remains the deepest therapeutic category, driven by precision medicine and strategic pharma demand. For a company raising a priced early round, this list identifies the firms with the most active recent presence in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.